ຫຸ້ນຂອງ Humanigen ຫຼຸດລົງ 67% ຫຼັງຈາກແບ່ງປັນຂໍ້ມູນທາງຄລີນິກໃໝ່ສຳລັບການປິ່ນປົວ COVID-19

Shares of Humanigen Inc.
HGEN,
80.10​-%
plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.’s
ຫຍ້າ,
+ 0.32%
Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen’s stock is down 19.6% this year, while the S&P 500
SPX,
0.29​-%
ໄດ້ຫຼຸດລົງ 19.9%.